07/05/2025 14:36
EQS-Adhoc: Change of President and CEO at Carl Zeiss Meditec AG
INFORMATION REGLEMENTEE

EQS-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Personnel
Change of President and CEO at Carl Zeiss Meditec AG

07-May-2025 / 14:36 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.



Change of President and CEO at Carl Zeiss Meditec AG
 
Jena, May 7, 2025

The supervisory board of Carl Zeiss Meditec AG (ISIN: DE0005313704) in today’s meeting has agreed on a change in the Management Board of the company. Dr. Markus Weber, President and CEO of Carl Zeiss Meditec AG since January 1, 2022, will turn over his position to Maximilian Foerst, currently Head of ZEISS Greater China, on May 31, 2025. The handover is taking place at Dr. Weber’s own request and on best of terms with the Supervisory Board.

Maximilian Foerst joined Carl Zeiss AG in 1995 and, following initial roles in product management and marketing in the medical technology field, took over leadership of the Carl Zeiss sales and service companies in France and Korea and – since 2009 - ZEISS Greater China. Under his leadership, ZEISS achieved market leadership in the Refractive Laser business as well as a leading position in the intraocular lense business in China. The region Greater China is the largest single market for Carl Zeiss Meditec AG with a revenue share of 26% in fiscal year 2023/24.

Along with his new role as President and CEO of Carl Zeiss Meditec AG, Maximilian Foerst has also been nominated as an Executive Board member of Carl Zeiss AG and will take over Dr. Weber’s responsibilities. Dr. Weber will leave the Executive Board of Carl Zeiss AG likewise on May 31, 2025.

In the view of the Supervisory Board of Carl Zeiss Meditec AG, management continuity is assured via the internal succession. The Chief Financial Officer, Justus Felix Wehmer remains in office. Leadership of the Strategic Business Units Ophthalmology and Microsurgery remains unchanged as well.
 

 Contact for investors and press


Sebastian Frericks
Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: investors.med@zeiss.com


 


 


 


 


 


 


 


 


 




End of Inside Information

07-May-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com



Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: investors.meditec@zeiss.com
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2132254

 
End of Announcement EQS News Service

2132254  07-May-2025 CET/CEST











EQS-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Personnel


Change of President and CEO at Carl Zeiss Meditec AG


07-May-2025 / 14:36 CET/CEST


Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.


The issuer is solely responsible for the content of this announcement.






Change of President and CEO at Carl Zeiss Meditec AG
 

Jena, May 7, 2025


The supervisory board of Carl Zeiss Meditec AG (ISIN: DE0005313704) in today’s meeting has agreed on a change in the Management Board of the company. Dr. Markus Weber, President and CEO of Carl Zeiss Meditec AG since January 1, 2022, will turn over his position to Maximilian Foerst, currently Head of ZEISS Greater China, on May 31, 2025. The handover is taking place at Dr. Weber’s own request and on best of terms with the Supervisory Board.


Maximilian Foerst joined Carl Zeiss AG in 1995 and, following initial roles in product management and marketing in the medical technology field, took over leadership of the Carl Zeiss sales and service companies in France and Korea and – since 2009 - ZEISS Greater China. Under his leadership, ZEISS achieved market leadership in the Refractive Laser business as well as a leading position in the intraocular lense business in China. The region Greater China is the largest single market for Carl Zeiss Meditec AG with a revenue share of 26% in fiscal year 2023/24.


Along with his new role as President and CEO of Carl Zeiss Meditec AG, Maximilian Foerst has also been nominated as an Executive Board member of Carl Zeiss AG and will take over Dr. Weber’s responsibilities. Dr. Weber will leave the Executive Board of Carl Zeiss AG likewise on May 31, 2025.


In the view of the Supervisory Board of Carl Zeiss Meditec AG, management continuity is assured via the internal succession. The Chief Financial Officer, Justus Felix Wehmer remains in office. Leadership of the Strategic Business Units Ophthalmology and Microsurgery remains unchanged as well.
 

 Contact for investors and press



Sebastian Frericks

Head of Group Finance & Investor Relations

Carl Zeiss Meditec AG

Tel.: +49 3641 220-116

E-Mail: investors.med@zeiss.com





 



 



 



 



 



 



 



 



 





End of Inside Information


07-May-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com





























Language: English
Company: Carl Zeiss Meditec AG

Göschwitzer Str. 51-52

07745 Jena, Germany

Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: investors.meditec@zeiss.com
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2132254





 
End of Announcement EQS News Service




2132254  07-May-2025 CET/CEST







\"\"